NCT05878561View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
Essential Hypertension
Interventions
DRUG

Fimasartan + Indapamide

a fixed dose combination

DRUG

Fimasartan + Indapamide placebo

a fixed dose combination

Trial Locations (1)

14647

The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon-si

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY